Protein key to diagnosing, treating some cancers

By The Science Advisory Board staff writers

August 11, 2022 -- The pathway of a certain protein could lead to early diagnosis and targeted treatment of several cancers and brain disorders, according to Queen’s University Belfast in Northern Ireland researchers.

The molecular mechanisms of epithelial to mesenchymal transition (EMT) are essential for the migration of newborn neurons during brain development, but a defect in this process can also cause cancer metastasis. This discovery has ramifications for understanding cancer metastasis and brain development and could lead to earlier diagnosis and better treatments, according to the authors (Nature Cell Biology, August 8, 2022).

EMT enables cell migration and is vital for early development processes including brain development as well as for wound healing later in life. However, it's also used by cancer cells for metastasis. The scientists identified the protein ZNF827 as a critical regulator of EMT. The protein orchestrated a large-scale remodeling of the splicing landscape by recruiting HDAC1 for epigenetic modulation of distinct genomic loci. This slowed RNA polymerase II progression and altered the splicing of genes encoding key EMT regulators in cis.

The findings reveal an "unprecedented" complexity of crosstalk between epigenetic landscape and splicing program in governing EMT and identifies ZNF827 as a master regulator coupling these processes during EMT in brain development and breast cancer metastasis.

This discovery opens new opportunities for a therapeutic intervention against cancer and a better understanding of neurodevelopmental disorders involving defects in brain development, the authors said.

AI, computer models of brain cells open door to experiments not possible in lab
Cedars-Sinai Medical Center researchers used artificial intelligence (AI) to create what they contend are the most realistic and complex computer models...
Scientists identify diagnostic gene signature for breast cancer
Researchers have identified a diagnostic signature for genetic mutations and other abnormalities associated with drug resistance and poor outcomes in...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter